Wall Street Analysts Raise Mirum Pharmaceuticals Price Target to $151.64
Wall Street analysts covering Mirum Pharmaceuticals, Inc. (MIRM) have increased their average 12-month price target for the company to $151.64 per share, up from a previous average of $148.86. The updated figure reflects forecasts from 14 analysts, whose individual price targets span from $118 to $200.
The revised target suggests roughly 76% potential upside relative to the stock's closing price of $86.06 on October 9. Sentiment among covering analysts remains overwhelmingly positive, with all 14 maintaining a Buy rating on the stock and none recommending a Hold or Sell.
Investors will be watching whether upcoming corporate announcements and financial results help propel the stock toward Wall Street's higher forecasts. With price targets topping out at $200 per share, market participants will track how future operational developments influence analyst expectations.
Key points
- Analysts raised their average 12-month price target for Mirum Pharmaceuticals, Inc. from $148.86 to $151.64.
- The updated price target represents approximately 76% potential upside relative to the October 9 closing price.
- Individual price targets among 14 covering analysts range between $118 and $200 per share.
- All 14 analysts covering the company maintain a Buy rating on the stock.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the new average price target for Mirum Pharmaceuticals stock?
Wall Street analysts raised the average 12-month price target for Mirum Pharmaceuticals, Inc. to $151.64 per share, up from $148.86.
How much potential upside does the updated price target imply for MIRM?
Based on the closing price of $86.06 on October 9, the updated average target implies approximately 76% upside. Individual analyst forecasts range from $118 to $200 per share.
What is the overall analyst consensus rating for Mirum Pharmaceuticals?
The analyst consensus rating remains a unanimous Buy, with all 14 covering analysts rating the stock a Buy and none issuing Hold or Sell ratings.